image credit: Adobe Stock

Novo Nordisk achieve headline results with icodec insulin

October 4, 2022

Compared to once-daily basal insulin (insulin degludec or insulin glargine U100/U300) analogues, the 52-week ONWARDS 5 trial – an open-label efficacy and safety treat-to-target study of 1,085 insulin-naïve people with type 2 diabetes in a clinical practice setting – achieved its primary endpoint, demonstrating non-inferiority in reducing HbA1 at week 52.

From a baseline HbA1 of 8.9%, the once-weekly insulin icodec achieved a superior reduction in estimated HbA1 of -1.68%-points compared with -1.31%-points for once-daily basal insulins.

Read More on Pharmaphorum